These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or other approved labeling. Drug Details Company Name Business Partner Drug Name Generic Name Unique ID Studied Indications or Disease Phase Approved Drug Label Pfizer Inc. Aromasin exemestane NCT00036270, NCT00279448 Cancer, Breast Phase III http://media.pfizer.com/files/products/uspi_aromasin.pdf ; http://media.pfizer.com/files/products/ppi_aromasin.pdf Clinical Study Summary Protocol No. 971-ONC-0028-081 (United States) and EXEAPO-0028-118 (France): Randomized Phase III Study Of Exemestane For 5 Years Versus Tamoxifen For 2.5-3 Years Followed By Exemestane For A Total Of 5 Years As Adjuvant Therapy For Postmenopausal, Receptor Positive, Node Negative Or Node Positive Breast Cancer Patients. These two Pfizer sponsored trials are part of an international collaboration of investigators conducting 7 similar yet independent studies in 9 countries. These studies were designed to be part of the larger TEAM trial where the data from these 7 studies will be combined. A pre-specified analysis of the pooled data has been conducted. Links to ClinicalTrials.gov: 971-ONC-0028-081 (United States): http://www.clinicaltrials.gov/ct2/show/NCT00036270?term=971-ONC-0028-081&rank=1 EXEAPO-0028-118 (France): http://www.clinicaltrials.gov/ct2/show/NCT00279448?term=EXEAPO-0028-118&rank=1 Pfizer will use reasonable efforts to include accurate and up-to-date information on the ClinicalStudyResults.org web site. However, because the status of studies often changes, Pfizer can make no, and makes no, warranties or representations of any kind as to the currency or completeness of the information contained therein. You agree that access to and use of information posted by Pfizer on the ClinicalStudyResults.org web site is at your own risk. Pfizer disclaims all warranties, express or implied, including warranties of merchantability of fitness for a particular purpose. Pfizer shall not be liable for any damages, including without limitation, direct, incidental, consequential, indirect or punitive damages, arising out of access to, use of, or inability to use information posted by Pfizer on the ClinicalStudyResults.org web site, or any errors or omissions in the content thereof. The ClinicalStudyResults.org web site is maintained by PhRMA, a trade association of which Pfizer is a member. PhRMA had no role in the sponsorship or conduct of the studies posted by Pfizer on ClinicalStudyResults.org. Company Study Protocol No. TEAM Trial Back to Search Results